191 related articles for article (PubMed ID: 26702785)
1. The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic.
Makvandi M; Lieberman BP; LeGeyt B; Hou C; Mankoff DA; Mach RH; Pryma DA
Nucl Med Biol; 2016 Jan; 43(1):35-41. PubMed ID: 26702785
[TBL] [Abstract][Full Text] [Related]
2. Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for alpha radionuclide therapy.
Ogawa K; Mizuno Y; Washiyama K; Shiba K; Takahashi N; Kozaka T; Watanabe S; Shinohara A; Odani A
Nucl Med Biol; 2015 Nov; 42(11):875-9. PubMed ID: 26235266
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker.
Hou C; Tu Z; Mach R; Kung HF; Kung MP
Nucl Med Biol; 2006 Feb; 33(2):203-9. PubMed ID: 16546674
[TBL] [Abstract][Full Text] [Related]
4. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
[TBL] [Abstract][Full Text] [Related]
5. Targeted cancer cell ablation in mice by an α-particle-emitting astatine-211-labeled antibody against major histocompatibility complex class I chain-related protein A and B.
Li HK; Hasegawa S; Nakajima NI; Morokoshi Y; Minegishi K; Nagatsu K
Biochem Biophys Res Commun; 2018 Dec; 506(4):1078-1084. PubMed ID: 30409432
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacological characterization of 4-[125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: a high affinity sigma receptor ligand for potential imaging of breast cancer.
John CS; Vilner BJ; Gulden ME; Efange SM; Langason RB; Moody TW; Bowen WD
Cancer Res; 1995 Jul; 55(14):3022-7. PubMed ID: 7606722
[TBL] [Abstract][Full Text] [Related]
7. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with
Bäck T; Chouin N; Lindegren S; Kahu H; Jensen H; Albertsson P; Palm S
J Nucl Med; 2017 Apr; 58(4):598-604. PubMed ID: 27688477
[TBL] [Abstract][Full Text] [Related]
8. Quantification of activity by alpha-camera imaging and small-scale dosimetry within ovarian carcinoma micrometastases treated with targeted alpha therapy.
Chouin N; Lindegren S; Jensen H; Albertsson P; Bäck T
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):487-95. PubMed ID: 23358400
[TBL] [Abstract][Full Text] [Related]
9. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
Kennel SJ; Mirzadeh S; Eckelman WC; Waldmann TA; Garmestani K; Yordanov AT; Stabin MG; Brechbiel MW
Radiat Res; 2002 Jun; 157(6):633-41. PubMed ID: 12005541
[TBL] [Abstract][Full Text] [Related]
10. Radioiodination and preclinical evaluation of 4-benzyl-1-(3-[
Sadeghzadeh M; Alirezapour B; Charkhlooie GA; Baghery MK; Khorouti A
Ann Nucl Med; 2017 May; 31(4):335-346. PubMed ID: 28315150
[TBL] [Abstract][Full Text] [Related]
11. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors.
John CS; Vilner BJ; Geyer BC; Moody T; Bowen WD
Cancer Res; 1999 Sep; 59(18):4578-83. PubMed ID: 10493511
[TBL] [Abstract][Full Text] [Related]
12. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
Reilly RM; Chen P; Wang J; Scollard D; Cameron R; Vallis KA
J Nucl Med; 2006 Jun; 47(6):1023-31. PubMed ID: 16741313
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and pharmacological evaluation of ¹¹C-labeled piperazine derivative as a PET probe for sigma-2 receptor imaging.
Selivanova SV; Toscano A; Abate C; Berardi F; Müller A; Krämer SD; Schibli R; Ametamey SM
Nucl Med Biol; 2015 Apr; 42(4):399-405. PubMed ID: 25637276
[TBL] [Abstract][Full Text] [Related]
15. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
Akabani G; Kennel SJ; Zalutsky MR
J Nucl Med; 2003 May; 44(5):792-805. PubMed ID: 12732682
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of new α-radionuclide therapy targeting LAT1: 2-[
Ohshima Y; Suzuki H; Hanaoka H; Sasaki I; Watanabe S; Haba H; Arano Y; Tsushima Y; Ishioka NS
Nucl Med Biol; 2020; 90-91():15-22. PubMed ID: 32916470
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.
Lahorte CM; Bacher K; Burvenich I; Coene ED; Cuvelier C; De Potter C; Thierens H; Van de Wiele C; Dierckx RA; Slegers G
J Nucl Med; 2004 Jun; 45(6):1065-73. PubMed ID: 15181142
[TBL] [Abstract][Full Text] [Related]
18. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.
Andersson H; Elgqvist J; Horvath G; Hultborn R; Jacobsson L; Jensen H; Karlsson B; Lindegren S; Palm S
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3914S-21S. PubMed ID: 14506189
[TBL] [Abstract][Full Text] [Related]
19. Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.
Thorek DLJ; Ku AT; Mitsiades N; Veach D; Watson PA; Metha D; Strand SE; Sharma SK; Lewis JS; Abou DS; Lilja HG; Larson SM; McDevitt MR; Ulmert D
Clin Cancer Res; 2019 Jan; 25(2):881-891. PubMed ID: 30254080
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of 4 and 6-carbon spacer conformationally flexible tetrahydroisoquinolinyl benzamide analogues for imaging the sigma-2 receptor status of solid tumors.
Lee I; Lieberman BP; Li S; Hou C; Makvandi M; Mach RH
Nucl Med Biol; 2016 Nov; 43(11):721-731. PubMed ID: 27589334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
